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Abstract
Background: Colorectal cancer (CRC) is a leading cause of cancer morbidity and mortality. People at higher risk
are those individuals with a family history of CRC and familial adenomatous polyposis. Prevention and screening
are two milestones for this disease. The aim of this study is to evaluate the chemopreventive role of non-steroidal
anti-inflammatory drugs (NSAIDs), including aspirin and cyclooxygenase 2 inhibitors, some micronutrients (folic
acid, calcium, selenium, antioxidants) and probiotics.
Discussion: The studies on aspiring reported promising results, but it is debatable whether aspirin should be used
as chemoprevention, because of its side effects and because of poor efficacy evident in subjects at high risk.
Similar results were reported for other non-aspirin NSAIDs, such as sulindac and celecoxib, which the potential
adverse effects limit their use. Selenium role in prevention of various types of cancer as well as in colon adenomas
are often inconclusive or controversial. Several studies suggested that calcium may have a possible
chemopreventive effect on colon adenomas and CRC, although contrasting results are reported for the latter.
A recent meta-analysis including 13 randomized trial suggested that folic acid supplementation had not a
chemiopreventive action on CRC. Several studies investigated the association between antioxidants, administered
alone or in combination, and CRC risk, both among general and at risk population, but only few of them
supported statistically significant results.
Conclusion: The results of this literature review showed an unclear role in CRC prevention of both
pharmacological and dietary intervention. Despite several options are available to prevent colon cancer, it is
challenging to identify a correct strategy to prevent CRC through pharmacological and dietary intervention due to
the long latency of cancer promotion and development. Since some of the drugs investigated may have uncertain
individual effects, it can be suggested to potentiate such effects by adding them together.
Background
During last decades, several progresses have been done
in cancer prevention [1]. The introduction of the laparo-
scopic approach allowed a less invasive surgical therapy
(as tertiary prevention) for colorectal cancer (CRC)
patients [2-6]. Regarding the secondary prevention, the
screening programs demonstrated high value in certain
types of cancer, but only allow preventing progression
of already existing malignancies that often occur in
elderly subjects [7,8]. Regarding CRC, which is the third
most common cancer in males and the second in
females [9], special attention has been paid to the ade-
nomatous polyp or adenoma, which is an important surro-
gate endpoint for colon cancer [10]. The adenoma is a
premalignant lesion, usually asymptomatic, which occurs
generally among older individuals, especially those more
than 50 years old [10]. It is common that colon cancers
emerge from adenomas, although not all adenomas evolve
in cancers [10,11]. However, since new adenomas often
develop in individuals who have had previous adenomas
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that were ablated, a preventive intervention may focus on
prevent formation of new adenomas as a surrogate marker
of colon cancer.
Despite the recent development in drug therapy against
CRC are promising [12,13], primary prevention interven-
tions against colorectal cancer mostly involve dietary mea-
sures, although a pharmacological approach demonstrated
to be effective in selected subjects. Thus, the aim of this
study is to review the effects of dietary and pharmacologi-
cal experimental approach to identify chemopreventive
agents and strategies against the CRC.
Aspirin
Acetylsalicylic acid (aspirin) is one of the most widely
used drugs in the world [14]. Aspirin is a salicylate drug,
nowadays mainly used as an analgesic to calm minor
aches and pains, as an antipyretic to reduce fever, and as
an anti-inflammatory medication. It also plays an impor-
tant role in hypertension and in other cardiovascular dis-
eases [15]. In fact, it has been long known that thanks to
his antiplatelet effect by inhibiting the production of
thromboxane, aspirin is used long-term, at low doses, to
help prevent ischemic events [16]. The main undesirable
side effects of aspirin assumption are gastrointestinal
ulcers and stomach bleeding, especially in higher doses.
Nausea and dyspepsia are milder adverse reactions, and
fortunately the most frequent [17]. Because of his already
mentioned antiplatelet effect, the use of aspirin in asso-
ciation with other drugs that increase the risk of bleeding
must be controlled. In addition, aspirin should be used
with prudence in the elderly, because of the risk of Reye’s
syndrome [18] and in individuals with favism, although
recent studies have shown a good tolerance to low doses
of the drug in these patients [19].
Despite aspirin at present is not a certified medicinal
for cancer prevention, several lines of evidence propose
that long-term use of aspirin might decrease the risk of
some cancers, particularly gastrointestinal tumors [20].
Different researches have observed an inverse associa-
tion between continuous aspirin intake and risk of CRC
[21-23]. In 1991, Thun et al. [24] recruited 662,424
patients, proving a reduced risk of CRC mortality over a
6-year period, thanks to aspirin use at least 16 times per
month. Similar findings were observed in subsequent
studies, such as the Health Professionals Follow-up
Study (HPFS) and the US Nurses’ Health Study (NHS)
cohort, which talked about an hazard reduction respec-
tively equal to 21% in a cohort of men and 23% in a
cohort of women only [25,26]. Two American [27,28]
and two European randomized studies [29,30] compared
aspirin against a placebo group in the intermediate risk
population, consisting of patients with history of adeno-
mas. Sandler et al. [27] showed that daily aspirin intake
for one year reduced by approximately 35% the risk of
adenoma, of both the number and the rapidity of
growth, in patients who had previously undergone surgi-
cal resection of colorectal cancer. The other study
conducted in USA was a randomized, double-blind, pla-
cebo-controlled trial about the efficacy of different doses
of oral aspirin, comparing 81 mg and 325 mg of aspirin
per day with placebo in patients with a recent history of
adenoma and finding that the relative risk (RR) of ade-
noma reappearance was lower in the 81 mg group than
in the 325 mg one [28]. The same result about the effec-
tiveness of aspirin in lowering the recurrence of colorec-
tal adenomas in intermediated risk population has been
demonstrated by Logan et al. [29], which also underlined
a possible role of the drug in preventing the development
of advanced lesions. In this 3-year study, folic acid was
prescribed in addiction to aspirin to half of the patients
in both the treated and the control group, but the evi-
dence showed no protective efficacy conferred by this
other medicine. Finally, in a study of 238 patients, with a
history of adenoma, randomized to receive placebo,
160 mg aspirin, or 300 mg aspirin, the RR of adenoma
recurrence was 0.61 in the 300 mg group, and 0.85 in the
160 mg group [30]. Besides, the RR for recurrent adeno-
mas for the 300-mg group versus the 160 mg group
was 0.72.
Although these promising result, it is debatable whether
aspirin should be used as chemoprevention, because of its
side effects and because of poor efficacy evident in subjects
at high risk. Some studies specifically investigated the
association between the use of aspirin and the risk of
intestinal neoplasms among high risk population, such as
patients with hereditary conditions with a known genetic
basis, for instance adults with Lynch syndrome) [31] and
people with familial adenomatous polyposis (FAP) [32].
Both studies compared aspirin (600 mg daily), with or
without resistant starch (30 g daily), to resistant starch
alone or placebo, demonstrating no benefits in reducing
polyp number or the incidence of colorectal cancer.
Nevertheless, the Colorectal Adenoma/carcinoma Preven-
tion Program 1 (CAPP1) study founded a significant
decline in polyp size among patients with FAP treated
with aspirin for more than 1 year [32]. A probable differ-
ent mismatch-repair-dependent neoplastic pathway, char-
acterized by low susceptibility to protection from aspirin,
may explain the absent efficacy of this drug in high-risk
patients compared with those at intermediate risk [31].
Finally, several researches that analyzed the effect of
aspirin on adenomas and CRC in low-risk populations
have found that alternate day use of low-dose aspirin for
an average 10 or 5 years of treatment did not lower CRC
risk [33,34]. Other authors, instead, studied the effects of
daily administered high dose of aspirin (300-500 mg/day
for 1-7 years and 300-1500 mg/day for 5-6 years) but still
no inverse relationship between aspirin use and risk of
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adenomas or CRC was found [35,36]. On the other hand,
an updated analysis of these cohorts made by Flossmann
et al. [37], observed that over a follow-up period of up to
23 years there was a statistically significant 26% reduction
in the relative risk of CRC incidence in aspirin users versus
nonusers.
Regarding the possible mechanism of action of aspirin
in preventing oncological diseases, it may depends on its
most well-known pharmacologic effect such as the per-
manent modification of the COX enzymes, which are
responsible for the conversion of arachidonic acid to
prostaglandins, relating eicosanoids. Cyclo-oxygenase-1
is in many tissues, while the isoenzyme 2 of COX is
almost undetectable in normal tissue and produces pros-
taglandins for inflammatory response. COX-2 is up-regu-
lated in many cancers such as CRC but also in colorectal
adenomas [38,39]. In fact, as suggested by different stu-
dies COX-2 may play a role in colorectal tumor growth
and development, by its effect on pro- and anti-inflam-
matory cytokines, migration, apoptosis transcription, and
angiogenic factors [40,41]. It seems that the chemopre-
ventive effect, still unclear, of aspirin against CRC is due
to the COX-2 inhibitory action both directly, by suppres-
sing prostanoids release, and indirectly, through its
effects on platelets [38]. In fact, aspirin mediated inhibi-
tion of platelets may block the liberation of mediators
that promote COX-2 expression in nucleated cells at
sites of mucosal injury [39]. There are also some non-
COX-related pathways that may explain aspirin’s anti-
neoplastic effects, such as the promotion of apoptosis in
cancer cells [42], the diminution of microsatellite
instability in CRC cells [43], the modulation of expres-
sion of transcription factors induced by oncogenes and
the induction of spermidine/spermine N1-acetyltransfer-
ase, which results in modulation of polyamine synthesis,
essential for neoplastic cell growth [44,45].
Non-aspirin non-steroidal anti-inflammatory
drugs (NSAIDs)
Study on chemoprevention of CRC and/or adenomatous
polyps in populations at differing risks investigated the
role of NSAIDs, including aspirin and cyclo-oxygenase-2
(COX-2) inhibitors. The only drug authorized for this
purpose by the European Medicines Agency is the Cele-
coxib a non-aspirin NSAIDs selectively blocker COX-2.
It was demonstrated to be effective in reducing the
number of polyps in patients with familial adenomatous
polyposis (FAP) and it is also used in addition to surgery
and endoscopic surveillance [46]. Many controlled trials
have been made in different countries to investigate
NSAIDs efficacy and safety in adenomas and cancer
chemoprevention. A randomized, double-blind, placebo-
controlled study on 41 young subjects (8-25 years) geno-
typically, but not phenotypically, affected with FAP were
treated with sulindac or placebo for 48 months. The
results showed that standard doses of sulindac (75 or
150 mg twice a day) did not prevent the development of
adenomas in subjects with FAP [47]. A previous trial
conducted on 22 patients with FAP receiving sulindac at
the dose of 150 mg orally twice a day for nine months
showed a reduction in numbers and size of colorectal
adenomas. However, after one year of follow-up, this
treatment demonstrated only a partial efficacy, and can-
not replace colectomy as primary therapy [48]. Nugent
et al. [49] conducted a randomized trial on 24 patients
with FAP and advanced duodenal polyposis who had
previously undergone prophylactic colectomy. Patients
received sulindac at the dose of 400 mg once a day for
six months. At the end of the treatment period a signifi-
cant regression both in duodenal and rectal polyps was
found.
The effectiveness of sulindac in inducing the regression
of rectal polyps in FAP was also demonstrated by another
double-blind trial conducted on 10 patients with rectal
polyps and previously treated by colectomy and ileorectal
anastomosis [50]. Patients received sulindac (300 mg/day)
or placebo during two 4-month periods separated by a
1-month washout phase. The authors observed significant
differences in complete and almost complete regression
between the sulinac and the placebo groups. Other pla-
cebo-controlled, double-blind trials, showed a significant
regression of colorectal adenomas in patients with FAP
using 400 mg of celecoxib twice daily [51] and a signifi-
cantly reduction of recurrence of colorectal adenomas
within three years after polypectomy using 400 mg of cele-
coxib once daily [52]. On the contrary, another study
showed that the inhibition of a COX-2 with a 150-200 mg
dose of a selective COX-2 inhibitor did not induce clini-
cally sufficient regression of adenomas in patients with
FAP in a limited (6-month) medication period [53].
Despite the positive results of the use of NSAIDs in
chemoprevention of CRC, the potential adverse effects
limit their use. Results from a trial conducted on 2.035
subjects that received 200 mg or 400 mg of calecoxib
twice daily for 3 years, found a reduction in the inci-
dence of colorectal adenomas, compared with the pla-
cebo one, but also an increased risk of cardiovascular
events. The RR was 2.6 (95% CI 1.1-1.6) and 3.4 (95%
CI 1.5-7.9) for low and high dose respectively [54].
These results are in according with a recent double-
blind trial on 1561 subjects with removed colorectal
adenomas followed for 5 years. At the end of the follow
up the incidence of new and advanced adenomas were
significantly lower in the celecoxib group than in the
placebo group, however renal/hypertension events (RR
1.35; 95% CI 1.09-1.68) and cardiac disorders (RR 1.59;
95% CI 1.12-2.26) were highter in the celecoxib group
[55].
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A more recent study focused on the effect of NSAIDs on
various pro- and anti-inflammatory cytokines, transcrip-
tion, and angiogenic factors that are involved in the pro-
motion and growing of many cancers. The findings
suggest that co-administration of Sulindac and Celecoxib
significantly reduce the angiogenic potential of the grow-
ing neoplasm, but its consumption is not toxic free
(serious adverse events to gastrointestinal, renal and cardi-
ovascular systems have been reported) [56]. A possible
solution for the adverse effect of NSAIDs used as treat-
ment of FAP could be the administration of colon-specific
delivery of these drugs. Lee et al. [57] has found that the
use of colon-specific prodrug of celecoxib may be a useful
strategy to reduce the toxic effect and improve the phar-
macological properties of celecoxib.
Selenium
Selenium is an essential micronutrient present in nature
implicated in numerous biological functions, such as a
protective effect against oxidative damage of cells, for-
mation of thyroid hormones and modulation of immune
system [58,59]. Most of the selenium in the body comes
from diet. The aliments richest in selenium are liver, fish,
poultry and wheat. The recommended daily intake of
selenium varies from 60 μg/day for women, to 70 μg/day
for men [59]. Selenium role in prevention of various
types of cancer as well as in colon adenomas are often
inconclusive or controversial. An experimental study
attributed the potential preventive action of selenium to
its role in the acceleration of DNA repair and in the
reduction of DNA damage, with a decrease in number of
mutations that ultimately contribute to carcinogenesis
[60]. Another possible mechanisms involved could be the
induction of apoptosis through the activation of caspase-
3 and the modulation of glutathione and mitochondrial
functions [61].
Clark et al. [62] in a multicenter, double-blind, rando-
mized, placebo-controlled cancer prevention trial con-
ducted on 1312 subject with a history of basal cell or
squamous cell carcinomas of the skin (receiving 200 µg of
selenium or placebo per day) showed that the daily admin-
istration of selenium had no protective effect against the
development of skin cancer. Nevertheless, a significant
reductions in total cancer mortality in selenium treatment
group (RR 0.50; 95% CI 0.31-0.80) and in total cancer inci-
dence (RR 0.63; 95% CI 0.47-0.85) was found. Conversely
other studies didn’t found a protective role of selenium in
cancer [63-65].
A meta-analysis on antioxidant supplements for pre-
vention of gastrointestinal cancers confirmed the no
role of selenium in cancer prevention with a RR of 0.48
(95% CI 0.22-1.05) [66]. However in four of the fourteen
trials evaluated, selenium showed significant beneficial
effect on the incidence of gastrointestinal cancer (RR
0.50; 95% CI 0.35-0.71). The authors pointed out that
this result might be biased because of low methodologi-
cal quality in three of four trials.
On the preventive effect of colorectal adenoma sele-
nium showed a significant effect in specific group of
subject. An inverse association between serum selenium
and advanced colorectal adenoma was found in current
smoker (OR 0.27; 95% CI 0.11-0.66) and in subject with
the lowest tertile of baseline selenium (OR 0.27; 95% CI
0.09-0.77) [67]. These results are also confirmed by
another randomized trial on 758 cases and 767 sex- and
race-matched controls, where an OR of 0.63 (95% CI
0.47-0.84) and 0.44 (95% CI 0.24-0.81) were found for
the lowest quintile of baseline selenium and current
smokers, respectively [68]. Finally a more recent double-
blind randomized trial conducted on 411 patients who
had undergone a polypectomy, showing that the co-
administration of selenium with other antioxidants sig-
nificantly reduced the risk of adenoma recurrence in
these patients (HR 0.61; 95 % CI 0.41-0.92) [69].
Calcium
Calcium is essential for living organisms being involved in
biological processes and being one of the main compo-
nents of bones, teeth and nails. It is not currently a recog-
nized chemopreventive agent for colon cancer but its
intake is recommended in cases of deficient such as osteo-
porosis or in older adults. The use must be controlled and
limited in cases of kidney failure, sarcoidosis or nephro-
lithiasis and its administration is contraindicated in the
patients with hypercalcaemia and hypercalciuria. In case of
excess can cause gastrointestinal disturbances, bradycardia
and arrhythmias [70].
The mechanisms of action of calcium implicated in the
inhibition of colorectal carcinogenesis include the control
of cell proliferation, differentiation, and apoptosis.
Numerous input signals and intracellular pathways are
responsive to calcium and the response of a cell is strictly
contextual and linked to the cell type [71]. The modula-
tion of calcium-sensing receptors with the following
cascade of intracellular events and the direct role as acti-
vator/cofactor in protein kinase C activation are only two
of the essential role of calcium in the cell growth and dif-
ferentiation. Furthermore calcium is also involved in the
transcription process through the direct influence of
CREB (cAMP response element-binding protein) [72]. In
particular, colonocytes respond to calcium exposure with
the acquisition of a differentiated phenotype and their
sensibility to calcium remain until the disruption of the
calcium signaling differentiation-inducing network by the
neoplastic process [73]. There is also some evidence on
normal and transformed colonic cells of the direct anti-
proliferative, differentiation and apoptosis-inducing
action of calcium [74,75].
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Several studies suggested that calcium may have a possi-
ble chemopreventive effect on colon adenomas and CRC.
A recent analysis conducted on 1.235 subjects (420 with
CRC and 815 controls) investigated the dietary calcium
intake and its possible interactions with calcium-sensing
receptor (CASR) gene polymorphisms on colorectal cancer
risk. A food frequency questionnaire and single nucleotide
polymorphisms (SNPs) of CASR research were performed
and in all of the polymorphisms examined a significant
higher odds ratios was found in the low-calcium-intake
group compared to the high-calcium-intake group [76]. In
subject with a history of adenoma many randomize trial
found a slightly effect of calcium. Thomas et al. [77]
showed that calcium reduces colorectal cell turnover but
no effect on the number, size or distribution of rectal
polyps in a double-blind study carried out on 25 patients
with FAP receiving supplemental calcium carbonate
(1.5 g/day) or placebo tablets for 6 months. Another study,
performed on patients that received calcium gluconolac-
tate and carbonate (2 g elemental calcium daily) or pla-
cebo for 3 years, showed a modest but not significant
reduction in the risk of adenoma recurrence (OR 0.66 95%
CI 0.38-1.17) [78] On the contrary, a trial performed on
930 subject receiving 1.2 g of elementary calcium daily for
4 years, showed that the calcium group, compared with
the placebo one, had a lower risk to have at least one ade-
noma (OR 0.81; 95% CI 0.67-0.99) and also in the average
number of adenomas (OR 0.76; 95% CI 0.60 to 0.96) [79].
In a prospective intervention study, 116 polyp-bearing
patients received 1.6 g/day of calcium combined with
some antioxidants (beta-carotene, vitamin E, vitamin C,
selenium) were followed for 3 years. At 3 years no differ-
ences were found on polyp growth between the interven-
tion and the placebo group. However a significant
reduction in the number of new adenomas was found,
suggesting a possible protective role of calcium in the for-
mation of new adenomas [80]. A most recent study asses-
sing the predictive value of CRC risk factors for the
detection of advanced colorectal adenoma on 1236 ran-
domly selected subject, confirmed that calcium intake
could have a small protective effect (OR 0.99 per mg; 95%
CI 0.99-1.00) [81].
Regarding the CRC, a published meta-analysis on six-
teen trials investigated the effect of calcium supplements
without co-administered vitamin D on cancer risk find-
ing that calcium did not alter the risk of colorectal
cancer (RR 1.38; 95% CI 0.89-2.15) [82]. Conversely,
another study on 85,903 men and 105,108 women
examined the associations of intakes of calcium and
vitamin D with CRC risk reporting an inverse associa-
tion with CRC both for calcium intake [men (RR 0.70;
95% CI 0.52-0.93; p for trend <0.05); woman (RR 0.64;
95% CI 0.50-0.83; p for trend <0.05)] and dairy products
[men (RR 0.77; 95% CI 0.59-1.01; p for trend <0.05);
women (RR 0.66; 95% CI 0.49- 0.89; p for trend <0.05)
[83]. As the previous study, other authors investigated
the associations between the consumption of dairy foods
and calcium with cancer risk. One of these studies con-
ducted on 36,965 men and 16,605 women cancer cases
failed in found a linear association between calcium
intake and cancer [84]. However dairy food and calcium
intakes were significantly associated with digestive sys-
tem cancer (RR 0.84; 95% CI 0.77-0.92 in men, and RR
0.77; 95% CI 0.69-0.91 in women) and particularly with
CRC both in men and women. Cho et al. [85] analyzed
a pool of 10 cohort studies included 534,536 individuals,
among whom 4,992 incident cases of colorectal cancer.
Compared with the lowest intake category of milk, diet-
ary calcium and total calcium the RR for the highest
category were 0.85 (95% CI 0.78-0.94; p for trend <0.05),
0.86 (95% CI 0.78-0.95; p for trend <0.05) and 0.78 (95%
CI 0.69- 0.88; p for trend <0.001), respectively. These
results are also confirmed by a meta-analysis conducted
to evaluate the relationship between the consumption of
dairy products, calcium, vitamin D and the inhibition of
the development of CRC [86]. Data from 60 epidemiolo-
gical studies enrolling 26.335 CRC cases were analyzed.
High milk and dairy product intake RR on colon cancer
risk were, respectively, 0.78 (95% CI 0.67-0.92) and 0.84
(95% CI 0.75-0.95). Furthermore a high calcium intake
was found to reduce CRC risk.
Other studies investigated the role of calcium or calcium
plus vitamin D in CRC prevention focusing their research
on population subgroups. The trial reported by Lappe et
al. [87] was conducted on 1,179 postmenopausal women
divided in three groups: calcium alone (1.4-1.5 g/day),
calcium (1.4-1.5 g/day) plus vitamin D (1100 IU) and pla-
cebo. The treatment period was four years as well as the
follow up period. The results showed that calcium plus
vitamin D (RR 0.40; 95% CI 0.20-0.82) but not calcium
alone (RR 0.53; 95% CI 0.27-1.03) reduce all-cancer risk in
these subject. On contrary the Wactawski et al. [88] study
performed on 36,282 postmenopausal women received
calcium 1 g/day plus vitamin D 400 IU/day or placebo for
7 years found no significant effect of daily supplementa-
tion of calcium with vitamin D on colorectal cancer inci-
dence. Another study on women with a prospective
cohort of 45,354 subjects without a history of colorectal
cancer followed for 8.5 years found an approximately 25%
reductions CRC risk for both high dietary and supplement
calcium intake [89]. Moreover a mayor protective effect
was showed for the simultaneously high consumption of
calcium, both for dietary and supplement (RR 0.54; 95%
CI 0.37-0.79).
Folic acid
Folic acid is a water-soluble B vitamin needed for all the
reactions of synthesis, repair and methylation of DNA,
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homocysteine metabolism (methylation) and other
important biochemical reactions [90]. Humans cannot
synthesize folate de novo and the recommended dietary
intake change with age, sex or other conditions such as
pregnancy or lactation. Therapy with folic acid supple-
ment is indicated in pregnancy to reduce the risk of
anemia and to prevent the occurrence of neural tube
defects in the fetus [91]. It is also indicated, in combina-
tion with vitamin B12, in cases of megaloblastic anemia
caused by insufficient dietary intake, and also for the
anemia prophylaxis in chronic haemolytic states, malab-
sorption, or in renal dialysis. Important adverse effects
due to folic acid supplementation are very rare, except
for some gastrointestinal disorder.
A diet low in folate could be implicated in the onset of
many cancers due to folic acid role in stability of DNA by
regulating DNA biosynthesis, repair and methylation
[92]. In fact, the altered DNA and RNA methylation, and
the disruption of DNA integrity and repair, lead to DNA
aberrations with a higher risk of developing cancers and
in particularly the colorectal one [93]. Furthermore, the
results of a randomized trial conducted on fourteen sub-
jects with adenoma receiving 400 mcg/day or placebo for
10 weeks, indicated that folic acid can modify gene
expression [94].
The association between diminished folate status or
folate supplement and colorectal carcinogenesis had been
investigated in many studies. Baron et al. [95] to study
the protective effect of fruits and vegetables against the
risk of CRC administered a food-frequency questionnaire
to patients with adenoma, at baseline and four years
later. The obtained results showed a protective effect of
folic acid against CRC, however after adjustment for
intake of dietary fiber and fat, folate supplements was not
associated with a reduction in CRC risk. Furthermore the
alcohol intake that can reduce circulating folate levels
and interfere with some of its biochemical actions was
investigated. Findings reported a significant association
between alcohol intake and increased risk of adenoma
recurrence (OR 2.04; 95% CI 1.28-3.26) both for man and
woman. Similarly another study showed the same results
for high alcohol intake, but found more consistent results
on the protective effect of high dietary folate, in women
RR 0.66 (95% CI 0.46-0.95) and men RR 0.63 (95% CI
0.41-0.98) [96]. On the contrary, a randomized study on
women with high risk of cardiovascular disease, receiving
folic acid 2.5 mg/day, vitamin B6 50 mg/day and vitamin
B12 1 mg/day or placebo for 7 years, showed that the
combined intake of these components did not have a sig-
nificant effect on the risk of cancer occurrence ( HR 0.97;
95% CI 0.79-1.18) [97].
In a double-blind, placebo-controlled trial on 137 sub-
jects with adenomatous polyps, patients received 5 mg/day
of folic acid for 3 years showed a significant reduction in
the recurrence of colonic adenomas compared to the pla-
cebo group [98]. Another trial conducted on 216 patients
with atrophic gastritis receiving different combination of
folic acid and beta-carotene, demonstrated a lower risk of
gastrointestinal cancers in the folic acid group (OR 0.12;
95% CI 0.03-0.51) [99]. Different findings were found by
Logan et al. [29] in a multicenter, randomized, double-
blind trial on 945 adenoma patients, in which a supple-
mentation of 0.5 mg/day of folic acid for 3 years showed
no effect on adenoma recurrence (RR 1.07; 95% CI 0.85-
1.34). The same result were showed by a double blind pla-
cebo controlled trial conducted on patients with a recent
history of colorectal adenomas who received folic acid
(1 mg/day) with or without aspirin (81-325 mg/day) for
three years. Both at three and five years follow up folic
acid was not found to reduce colorectal adenomas [100].
Finally, a recent meta-analysis including 13 randomized
trial confirmed these findings, suggesting that folic acid
supplementation had not a chemiopreventive action on
CRC (RR 1.01; 95% CI 0.82-1.23) [101].
Probiotics
According to the official definition of FAO and WHO,
probiotics are “live organisms which, when administered
in adequate amounts, bring benefit to the health of the
host” [102]. The mechanisms by which probiotics may
inhibit colon cancer are not yet fully understood. How-
ever, there is evidence for a reduction in the inflammatory
response to host flora, alterations in the metabolic activ-
ities of intestinal bacteria, a reduction in the numbers of
bacteria involved in pro-carcinogenic and mutagenic path-
ways, and the production of anti-tumorigenic and muta-
genic substances [103]. In an experimental study, Ma et al.
[104] showed that the probiotic Bacillus polyfermenticus,
through the reduction of ErbB2 and ErbB3 receptors
(known to have essential roles in tumor development),
suppressed colon cancer cells growth both in vitro and in
vivo. Another study conducted on animal models showed
that the intake of probiotics is associated with anticarcino-
genic effects, due to the reduction of genotoxic agents in
the intestine and, concurrently to the rice in the produc-
tion of agents that deactivate these toxic components
[105]. Rafter et al. [106] conducted a study on 37 colon
cancer patients and 43 polypectomized patients that
received a synbiotic food composed of prebiotic and pro-
biotics or placebo for twelve weeks. Results showed that
the intake of this compound led to positive changes in the
bacterial flora and reduced the colorectal proliferation in
adenoma patient, but no in the cancer one. Similar results
on microflora changes were found in a double bind, pla-
cebo controlled study conducted on 20 subjects received
resistant starch or Bifidobacterium lactis, either alone or
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as a combined symbiotic preparation for four weeks. How-
ever, no significantly variation on epithelial proliferation
was observed [107].
Although many studies investigated the role of probio-
tics, there is still no clear clinical evidence of the protec-
tive role of probiotics in CRC. Further research is
needed to establish the real usefulness of probiotics in
CRC prevention [108].
Antioxidants
Antioxidants have been universally studied for preven-
tion of chronic disease, including inflammation, athero-
sclerosis, neurodegenerative diseases, and also cancer
[109-111]. A body of evidence suggests that oxidative
stress and the consequent peroxidation of lipid are
involved in these pathological states. Antioxidants, such
as various vitamins, may be introduced by “eating good”,
this means following a diet high in fruits and vegetables
or as dietary supplements. In fact it was seen that intake
of this kind of foods decrease the risk of developing can-
cer and cardiovascular disease [112].
Vitamins may be prescribed to prevent or treat their
corresponding deficit. Lack of vitamin C is a very rare
eventuality among people who eat a balanced diet. When
it occurs, it causes scurvy, which can lead to death if not
treated [109]. Also vitamin A (retinol) deficiency is
uncommon and it is correlated with ocular problems,
such as night blindness or xerophthalmia, and immune
system disorders. On the other hand, excessive doses of
the vitamin may be toxic, causing, among other things,
birth defects. Thus, retinol additions are contraindicated
specifically in pregnant women. Some studies reported
the necessity of vitamin E intake in adulthood, especially
if a possible cholestasis causes fats malabsorption. It
seems that this medicament could play a role in the treat-
ment of thromboembolic disease even if its use should be
done with prudent. As the previous one, an excess of
vitamin E (> 1 g/day) can produce side effects, such as
diarrhea and abdominal pain [113]. Finally, another
important antioxidant is vitamin D, which consists of
ergocalciferol, or vitamin D2, colecalciferol, also known
as vitamin D3, dihydrotachysterol, alfacalcidol and calci-
triol. Vitamin D2 is present in plants and some fish, so
that its deficiency results from a low dietary intake. Vita-
min D3 is produced in the skin by way of ultraviolet B
rays, thus a low exposure to sunlight can cause its defi-
ciency [114]. Several studies suggest that combined cal-
cium and vitamin D supplementation, but not limited to
vitamin D, prevented bone loss and it is recommended to
prevent and treat osteoporosis and in elderly patients
[115]. Some observational studies in humans and animal
models support that vitamin D has a favorable role in
cancer prevention, probably due to its action in the regu-
lation of cell growth and differentiation [116].
Focusing on CRC, observational analyses have found
an inverse correlation between calcium and vitamin D
intake and risk of CRC [78] and recurrent polyps [80].
Thomas et al. [77], considering a high-risk population
made by patients with familial adenomatous polyposis
(FAP) who had previously undergone total abdominal
colectomy with ileorectal anastomosis, observed that cal-
cium had no evident effect on the number, volume or
distribution of rectal polyps. Instead, there are no stu-
dies about the relationship between antioxidant and col-
orectal cancer risk in high risk group.
Considering people with previously adenomas or CRC,
it has been compared antioxidants, alone or in combina-
tion, against placebo. For example, Greenberg et al.
[117] selected 864 patients with an history of adenoma
removed from large bowel, and dividing them into dif-
ferent treatment groups, administered placebo, beta car-
otene (25 mg daily), vitamin C (1 g daily) and vitamin E
(400 mg daily), or beta carotene plus vitamins C and E.
The result of this investigation has demonstrated a lack
of chemopreventive action of antioxidants against CRC.
A Canadian study examined one hundred thirty-seven
people to value the effects of vitamins C and E against
placebo on the rate of recurrence of colorectal polyps,
but the correlation found is small and may be attributed
to chance (relative risk of 0.86) [118]. A combination of
vitamin A, C and E or lactulose were used to evaluate
their chemopreventive attitude against the reappearance
of colorectal polyps after their endoscopic removal, with
positive results. In fact, polyps recurred in 5.7% of the
individuals treated with vitamins, 14.7% of patients with
lactulose and 35.9% of untreated controls [119]. Similar
findings were obtained in an Italian work on 255 indivi-
duals after polipectomy [120].
MacLennan et al. [121] performed a randomized, par-
tially double-blinded, placebo-controlled trial to estimate
the efficacy on adenomas occurrence of lowering dietary
fat to 25% of total calories and fortifying diet with 25 g of
wheat bran daily and a capsule of beta carotene (20 mg
daily). This found that there was no statistically significant
prevention of new adenomas with any of the supplements,
although persons who received combined intervention of
low fat and added wheat bran developed no adenomas.
Several studies specifically investigated the association
between antioxidants, administered alone or in combi-
nation, and CRC risk among general population [63,99,
122-131]. The average duration of treatment was about
7 years and the follow-up of participants ranged from 5 to
12 years. Among the 14 analyses executed, only few of
them supported statistically significant results, such as the
one made by Malila et al. [128]. In this work, participants,
middle-aged male smokers, were randomly assigned to
four supplementation groups: alpha-tocopherol (AT),
50 mg/day; beta-carotene (BC), 20 mg/day; both AT and
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BC; and placebo. They found an increased CRC risk in the
group with a-tocopherol supplementation compared with
the no-a-tocopherol group. Instead b-carotene supple-
mentation had no effect on the incidence of adenomas.
However, according to the results from previous
reviews, there is no convincing evidence that antioxidant
supplements play a significant beneficial role in prevent-
ing adenoma or gastrointestinal cancer, including CRC
[122,132,133].
Conclusions
The results of this literature review showed an unclear
role in CRC prevention of both pharmacological and
dietary intervention. Despite several options are available
to prevent colon cancer, it is challenging to identify a
correct strategy to prevent CRC through pharmacologi-
cal and dietary intervention due to the long latency of
cancer promotion and development. Since some of the
drugs investigated may have uncertain individual effects,
it can be suggested to potentiate such effects by adding
them together.
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